thalidomide has been researched along with Hypercalcemia in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hypercalcemia: Abnormally high level of calcium in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The impact of high dose dexamethasone containing regimens with or without the novel agents thalidomide and bortezomib on the reversal of renal failure (RF) was evaluated in 41 consecutive newly diagnosed patients with multiple myeloma (MM) treated in a single institution." | 5.12 | Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. ( Anagnostopoulos, A; Bamias, A; Barmparousi, D; Dimopoulos, MA; Gika, D; Grapsa, I; Kastritis, E; Matsouka, C; Psimenou, E; Roussou, M, 2007) |
| "Multiple myeloma is an uncommon haematological cancer of plasma cells." | 1.48 | Multiple myeloma: Updated approach to management in 2018. ( Tomlinson, R, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tomlinson, R | 1 |
| Smith, D | 1 |
| Stevens, J | 1 |
| Quinn, J | 1 |
| Cavenagh, J | 1 |
| Ingram, W | 1 |
| Yong, K | 1 |
| Shibayama, H | 1 |
| Laubach, J | 1 |
| Richardson, P | 1 |
| Anderson, K | 1 |
| Moumas, E | 1 |
| Hanf, W | 1 |
| Desport, E | 1 |
| Abraham, J | 1 |
| Delbès, S | 1 |
| Debiais, C | 1 |
| Lacotte-Thierry, L | 1 |
| Touchard, G | 1 |
| Jaccard, A | 1 |
| Fermand, JP | 1 |
| Bridoux, F | 1 |
| Sullivan, E | 1 |
| Hoyle, C | 1 |
| Muthu Raja, KR | 1 |
| Rihova, L | 1 |
| Zahradova, L | 1 |
| Klincova, M | 1 |
| Penka, M | 1 |
| Hajek, R | 1 |
| Kastritis, E | 1 |
| Anagnostopoulos, A | 1 |
| Roussou, M | 1 |
| Gika, D | 1 |
| Matsouka, C | 1 |
| Barmparousi, D | 1 |
| Grapsa, I | 1 |
| Psimenou, E | 1 |
| Bamias, A | 1 |
| Dimopoulos, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of Thalidomide, Bendamustine and Dexamethasone (BTD) Versus Bortezomib, Bendamustine and Dexamethasone (BBD) in Patients With Renal Failure Defined as a GFR Below 30 Mls/Min[NCT02424851] | Phase 2 | 31 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02424851)
Timeframe: End of week 6 (after receiving two cycles of therapy)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (BBD) | 13 |
| Arm B (BTD) | 3 |
(NCT02424851)
Timeframe: 1 month post end of treatment and 1 year post randomisation
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (BBD) | 9 |
| Arm B (BTD) | 13 |
(NCT02424851)
Timeframe: End of weeks 3, 6, 9, 12 (after receiving 4 cycles of therapy), 30 days after final treatment and 12 months after randomisation
| Intervention | Events (Number) | |
|---|---|---|
| Serious adverse events | Adverse events | |
| Arm A (BBD) | 2 | 3 |
| Arm B (BTD) | 0 | 6 |
"The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is scored on a scale of 1 to 3: 1 (no problems), 2 (some problems), and 3 (extreme problems). Higher score equates to a worse outcome.~As stated in the official EQ-5D user guide, patient responses to the 5 questions were converted into a single index value as per Dolan P (1997). Modeling valuations for EuroQol health states. Med Care 35(11):1095-108. These index values, with country specific value sets, facilitate the calculation of quality-adjusted life years (QALYs) that are used to inform economic evaluations of health care interventions. In the UK, the values range from -0.594 to +1." (NCT02424851)
Timeframe: Baseline and 1 month follow up
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | 1 month FU | |
| Arm A (BBD) | 0.72 | 0.69 |
| Arm B (BTD) | 0.69 | 0.80 |
(NCT02424851)
Timeframe: End of 2nd treatment cycle, week 6
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Partial response | Minor response | No repsonse | |
| Arm A (BBD) | 2 | 9 | 4 |
| Arm B (BTD) | 0 | 7 | 6 |
3 reviews available for thalidomide and Hypercalcemia
| Article | Year |
|---|---|
[Supportive care in multiple myeloma for continuing anti-myeloma therapies].
Topics: Anemia; Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Dipho | 2014 |
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhi | 2011 |
[New insights in the treatment of myeloma with renal failure].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2011 |
1 trial available for thalidomide and Hypercalcemia
| Article | Year |
|---|---|
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; | 2007 |
4 other studies available for thalidomide and Hypercalcemia
| Article | Year |
|---|---|
Multiple myeloma: Updated approach to management in 2018.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Bortezomib; Disease Management; | 2018 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; | 2014 |
Calciphylaxis, occurring 10 weeks after hypercalcaemia, in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arterioles; Calciphylaxis; Chelation Therapy; Cyclop | 2011 |
Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; CD4-Positive T-Lymphocytes; Cyclophosphamide; | 2012 |